Currently out of the existing stock ratings of Geoff Meacham, 220 are a BUY (60.27%), 116 are a HOLD (31.78%), 29 are a SELL (7.95%).

Geoff Meacham

Work Performance Price Targets & Ratings Chart

Analyst Geoff Meacham, currently employed at CITI, carries an average stock price target met ratio of 65.16% that have a potential upside of 34.71% achieved within 240 days.

Geoff Meacham’s has documented 721 price targets and ratings displayed on 56 stocks. The coverage is on Healthcare, Technology sectors.

Most recent stock forecast was given on RNA, Avidity Biosciences at 10-Jun-2025.

Wall Street Analyst Geoff Meacham

Analyst best performing recommendations are on LYEL (LYELL IMMUNOPHARMA).
The best stock recommendation documented was for LYEL (LYELL IMMUNOPHARMA) at 10/30/2024. The price target of $1 was fulfilled within 2 days with a profit of $0.14 (16.28%) receiving and performance score of 81.4.

Average potential price target upside

of $88.91 (19.26%) on REGN (REGENERON PHARMACEUTICALS).
of $108.39 (66.74%) on BTAI (BIOXCEL THERAPEUTICS).
of $46.36 (18.28%) on LLY (ELI LILLY AND COMPANY).

ALXN Alexion Pharmaceuticals AMGN Amgen BIIB Biogen BMRN Biomarin Pharmaceutical BMY Bristol-Myers Squibb Company BTAI BioXcel Therapeutics CMPI Checkmate Pharmaceuticals CVAC CureVac NV GILD Gilead Sciences IIVI II-VI INCY yte INO Inovio Pharmaceuticals JNJ Johnson & Johnson LLY Eli Lilly and Company MRK Merck mpany MRNA Moderna PFE Pfizer REGN Regeneron Pharmaceuticals VRTX Vertex Pharmaceuticals KNSA Kiniksa Pharmaceuticals Ltd PMVP Pmv Pharmaceuticals PTCT PTC Therapeutics SGEN Seagen ABBV AbbVie ARAV Aravive CELG Celgene KYMR Kymera Therapeutics NBIX Neurocrine Biosciences ABOS Acumen Pharmaceuticals UTHR United Therapeutics VAXX Vaxxinity XLRN Acceleron Pharma ALNY Alnylam Pharmaceuticals ACHN Achillion Pharmaceuticals BBIO BridgeBio Pharma CMRX Chimerix CRBU Caribou Biosciences CRSP Crispr Therapeutics AG GRPH Graphite Bio ICPT Intercept Pharmaceuticals IPSC Century Therapeutics MYOV Myovant Sciences Ltd OMER Omeros PRTA Prothena plc RPRX Royalty Pharma Plc RTRX Travere Therapeutics TYRA Tyra Biosciences IGMS IGM Biosciences RANI Rani Therapeutics Holdings VIR Vir Biotechnology LIAN LianBio ADR AMLX Amylyx Pharmaceuticals JANX Janux Therapeutics RNA Avidity Biosciences LYEL Lyell Immunopharma NMRA Neumora Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hartaj Singh (OPPENHEIMER)